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Abstract
Background: Free circulating DNA (fcDNA) has many potential clinical applications, due to the non-invasive way in
which it is collected. However, because of the low concentration of fcDNA in blood, genome-wide analysis carries
many technical challenges that must be overcome before fcDNA studies can reach their full potential. There are
currently no definitive standards for fcDNA collection, processing and whole-genome sequencing. We report novel
detailed methodology for the capture of high-quality methylated fcDNA, library preparation and downstream
genome-wide Next-Generation Sequencing. We also describe the effects of sample storage, processing and scaling
on fcDNA recovery and quality.
Results: Use of serum versus plasma, and storage of blood prior to separation resulted in genomic DNA
contamination, likely due to leukocyte lysis. Methylated fcDNA fragments were isolated from 5 donors using a
methyl-binding protein-based protocol and appear as a discrete band of ~180 bases. This discrete band allows
minimal sample loss at the size restriction step in library preparation for Next-Generation Sequencing, allowing for
high-quality sequencing from minimal amounts of fcDNA. Following sequencing, we obtained 37×106-86×106
unique mappable reads, representing more than 50% of total mappable reads. The methylation status of 9 genomic
regions as determined by DNA capture and sequencing was independently validated by clonal bisulphite
sequencing.
Conclusions: Our optimized methods provide high-quality methylated fcDNA suitable for whole-genome
sequencing, and allow good library complexity and accurate sequencing, despite using less than half of the
recommended minimum input DNA.
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Background
Free circulating DNA (fcDNA) is DNA found in blood,
not associated with any cell fraction, and occurs pre-
dominantly as fragments of approximately 180 bases
with a smaller proportion of 360 base fragments [1,2].
The size suggests that it originates from apoptotic cells,
as it corresponds to the length of DNA wrapped around
mono- and di-nucleosomes, and to the two smallest
bands of the apoptotic DNA ladder, consistent with
DNA cleaved at inter-nucleosomal sites. The apoptotic
origin is further supported by the observation that
fcDNA is increased in mouse plasma when liver apoptosis
is induced by administration of anti-CD95 antibody [1].
Mice injected with anti-CD95 antibody showed an in-
crease in fcDNA, in parallel with the appearance of the
characteristic mono- and di-nucleosome sized bands on
a DNA gel. In contrast, mice in which liver necrosis was
induced by acetaminophen also showed an increase in
fcDNA; however this DNA was of high molecular weight,
and no increase in mono- or di-nucleosome bands was
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apparent. These data support the apoptotic rather than
necrotic origin of fcDNA.
The cell type which contributes most to the fcDNA in
healthy subjects is unclear. Measurement of Y-chromosome
DNA in the plasma of female patients receiving bone mar-
row from male donors showed that the DNA is predomin-
antly of donor origin, hence derived from hematopoietic
cells [3]. However, another group excluded T-cells as a
source of fcDNA based on lack of T-cell specific sequence
rearrangement [1]. fcDNA derived from cells other than
T-cells was measured using primers designed to amplify
the germline configuration of T-cell receptor β-chain
genes and T-cell receptor DNA was measured using
primers designed to amplify the rearranged T-cell receptor
β-genes found in mature T-cells. All fcDNA samples con-
tained the germline sequence of T-cell receptor β-chain
genes, while 18 of the 20 cancer fcDNA samples tested
showed no amplification with the T-cell specific primers,
indicating that T-cells are not a major source of fcDNA
in cancer patients.
Due to the non-invasive nature by which fcDNA can be
collected and examined, it carries tremendous potential in
clinical applications. One of the earlier clinical applications
of fcDNA is for non-invasive pre-natal diagnosis. Fetal
DNA can be detected in the maternal circulation starting
from about the 10th week of pregnancy [4], and quantita-
tion can accurately identify aneuploidies [5] without the
increased risk of miscarriage associated with more direct
sampling of fetus-derived tissues. Differences in DNA
methylation have been used to discriminate between fetal
and maternal DNA within the fcDNA pool [6,7]. These
differences may allow fetal DNA to be distinguished
from the large background of maternal DNA, and per-
mit a more accurate identification of fetus-specific
DNA changes.
More recently, studies have demonstrated that fcDNA
levels are increased in cancer patients as a result of
tumor cells shedding DNA into the blood (recently
reviewed in [8] and [9]), suggesting that fcDNA may be
useful for cancer detection. Moreover, studies have
demonstrated that cancer-derived fcDNA carries the
same molecular aberrations, including mutations and
methylation changes, as the source tumor, suggesting its
value as a cancer biomarker. For example, KRAS muta-
tions in fcDNA matching those in the solid tumor have
been detected in pancreatic cancer [10], colorectal can-
cer [11], and lung cancer [12], while mutated BRAF se-
quences have been detected in the fcDNA of melanoma
patients [13]. Jahr et al. showed that CDKN2A promoter
methylation was present in fcDNA and corresponding
solid tumors in 44% of cases examined, and absent from
healthy controls [1]. It has been shown that the presence
of colorectal and breast tumours can be determined from
the quantity of chromosomally aberrant DNA in the
circulation, without reference to specific individual mu-
tations [14]. In addition to detecting the presence of a
tumor, fcDNA is potentially a clinically useful tool for
characterizing heterogeneous patient subtypes and for
monitoring response to therapy [13]. Hence there is an
interest in the molecular characterization in fcDNA of
cancer patients in order to identify biomarkers for diag-
nosing the disease, determining tumor subtypes, and
tracking chemo-response.
Recent advances in whole-genome sequencing have
propelled our understanding of the germline and somatic
genomic alterations that are associated with cancer devel-
opment and progression (reviewed in [15]). Despite the
many benefits and clinical applications of fcDNA, whole-
genome analysis presents a number of technical chal-
lenges, particularly because in healthy individuals total
fcDNA is present at low concentrations (typically 1–
27 ng/ml) [8]. There are currently no definitive standards
for fcDNA collection, processing and whole-genome se-
quencing and existing protocols do not allow straight-
forward Next-Generation Sequencing (NGS) analysis of
the methylated fraction of fcDNA. While affinity purifi-
cation and parallel sequencing of methylated DNA per-
form robustly in samples where abundant starting
material is available [16], the limitations of these tech-
niques in plasma samples are two-fold: first, fcDNA oc-
curs at a very low concentration in control subjects, and
this makes selective binding of the methylated DNA
fraction difficult, as non-specific binding dominates the
captured sample; secondly, the methylation enrichment
step only recovers around 7% of the total DNA input
[17,18], which dramatically reduces the amount of DNA
available for NGS library construction and sequencing.
Hence, relatively large volumes of blood are required in
order to purify sufficient quantities of methylated fcDNA
to be compatible with downstream Next-Generation
Sequencing.
In an effort to address and resolve these technical
challenges, we report our comprehensive technical analysis
of fcDNA isolation from healthy subjects and enrichment
of methylated sequences followed by Next-Generation Se-
quencing. We describe a purification process optimized
for use with very dilute samples, methylation sequence en-
richment from low quantities of input DNA, and the library
quality and read numbers derived from these samples. Our
protocols allow for processing and high-quality genomic
methylation analysis from as little as 50 ng of total fcDNA,
including library preparation from less than half of the
recommended minimum input material.
Methods
Clinical sample collection
Blood collection from consented volunteers was approved
by the Human Research Ethics Committee at St Vincent’s
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Hospital (HREC 09/100). For plasma separation, blood
was collected in 10 mL Vacutainer plastic tubes which
contain K2EDTA as stabilizer (BD, USA) and for serum
separation, blood was collected in 8.5 mL Vacutainer
Serum Separation plastic tubes which contain silica par-
ticles as a clot activator and a gel which forms a barrier
between the serum and the clot after centrifugation
(BD, USA). Up to 50 mL blood (~22 mL plasma) were
collected from each volunteer for the time-course and
serum/plasma comparison experiments, and 80 mL blood
(~35 mL plasma) were collected from each of 5 healthy
female volunteer donors (mean age 58 years, range 53 –
72 years) for methylation enrichment and Illumina
Next-Generation Sequencing.
Blood storage time-course
For the blood storage time-course studies, blood was
stored for 4 hrs, 8 hrs, 24 hrs or 48 hrs after collection
at 4°C prior to separation of plasma. Control tubes were
processed immediately after collection. The time-course
experiment was carried out 3 times using blood from
separate donors. For methylation enrichment and se-
quencing studies, blood was stored for 6 hrs at 4°C prior
to plasma separation. At the appropriate time-point,
the blood tubes were centrifuged for 10 mins at 1370 g
at 4°C in a Rotanta 460R benchtop centrifuge (Hettich,
Germany). The plasma was carefully transferred into
fresh 15 mL or 50 mL tubes (Corning, USA), and centri-
fuged again as above to remove any remaining cell debris.
Plasma was stored at −70°C until DNA extraction.
Comparison of plasma and serum
In order to compare the DNA extracted from plasma and
from serum, blood was collected in K2EDTA tubes for
plasma separation and in clot activator containing tubes
for serum separation as described above. In addition, each
type of tube was pre-loaded with 70 ng of purified gen-
omic DNA (Roche) prior to blood collection. Both types
of tube were incubated for 30 mins at room temperature
to allow clot formation in the serum samples, and then
centrifuged as described above. Plasma and serum were
transferred into new tubes and centrifuged again as de-
scribed to remove any remaining cell debris. DNA was
extracted from the total volume of plasma or serum ob-
tained from each tube (~4 mL of plasma and ~3 mL of
serum) using the Circulating Nucleic Acids Kit (Qiagen)
according to manufacturer’s instructions, and extracted
DNA was visualized on a 1.5% TAE agarose gel post
stained with Gel Red stain (Biotium). DNA quantitation
by qPCR was carried out in triplicate for matched
plasma and serum from 3 separate donors, whereas gen-
omic DNA spiking and DNA agarose gel visualization
was carried in duplicate using blood from 2 separate
donors.
DNA extraction
For fcDNA extraction from small volumes of plasma
(200 μL), used for time-course DNA quantitation, the
QIAamp MinElute Virus Spin Kit was used following
manufacturer’s instructions. For fcDNA extraction from
larger volumes of plasma (≥4 mL up to 35 mL), used for
gel visualization of fcDNA, methylation enrichment, and
Next-Generation Sequencing, the Circulating Nucleic
Acids Kit (Qiagen) was used, with some modification to
the manufacturer’s protocol. Briefly, plasma was com-
bined with proportionately scaled volumes of proteinase
K and ACL buffer. Scaled quantities of carrier RNA
added to the samples were capped at 5 μg per sample in
order to minimize interference in downstream steps.
The samples were incubated at 60°C for 45 mins to
compensate for the slower heating of larger volumes. A
scaled volume of Buffer ACB was added to the digested
samples and they were incubated for 5 mins on ice, and
then applied in batches to the QIAamp mini column via
the tube extender. Where the total volume of digested
sample was ≤17.5 mL the sample was processed using a
single column. Samples >17.5 mL were split across 2
columns and processed in parallel. Once all the lysate
had been drawn through, the column was washed twice
with 700 μL of Buffer ACW1, then once with 750 μL of
Buffer ACW2. All further steps were carried out as
specified in the manufacturer’s protocols, except for the
56°C incubation to dry the columns, which was reduced
from 10 mins to 5 mins. The samples were eluted in 50 μL
of AVE Buffer followed by a second elution of 30 μL, and
a pooling of the separate elutions. Purified DNA samples
were stored at −80°C until further use.
fcDNA samples (1 μL) were analyzed for size distribu-
tion using the High Sensitivity DNA Chip (Agilent
Technologies) on an Agilent Bioanalyzer according to
manufacturer’s instructions, or on a 1.5% agarose TAE
gel post stained with Gel Red stain (Biotium).
Methylation enrichment
Methylated DNA sequences were isolated using the
MethylMiner kit (Invitrogen). Prior to commencing ex-
periments on fcDNA, we evaluated the performance of
the methylation enrichment protocol with low (100 ng)
DNA sample amounts, and developed a modified high-
stringency protocol to limit the amount of non-specific
DNA binding. Briefly, in the high-stringency protocol,
methyl-binding protein (MBD2) was coupled to the beads
following kit instructions; however, only 1 μL of beads per
sample was used. Once bead coupling was complete, all
subsequent wash steps were carried out in 300 mM NaCl
1X High Stringency Wash buffer (HSW buffer), instead
of 1X Wash/Bind buffer. 4X HSW buffer was made up
by combining the supplied High Salt buffer with the 5X
Wash/Bind buffer in a 1:2.67 volume:volume ratio. To
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capture methylated DNA 150 μL of DNA was mixed
with 50 μL of 4X HSW buffer and this solution was
used to directly resuspend the washed MBD-protein
coupled beads. The mixture was incubated on a rotor at
4°C overnight, the unbound DNA was removed, and the
beads were washed with HSW buffer 3 times. The cap-
tured DNA was eluted from the beads in a single high
salt elution step, ethanol precipitated as per kit instruc-
tions, resuspended in 35 μL H2O, and stored at −80°C
until further analysis. For samples processed using the
standard protocol, the manufacturer’s instructions were
followed without modification. The two protocols were
evaluated side by side with 100 ng and 400 ng DNA from
human peripheral blood mononuclear cells (PBMCs), and
from an SSSI-treated fully methylated control (Millipore).
Yield was determined by qPCR of the SFTA3 promoter
sequence as described below. Based on the data from
protocol evaluation, the high-stringency protocol was
used to isolate methylated sequences from fcDNA samples.
Blood from 5 separate donors was used for the fcDNA
methylation enrichment followed by Next-Generation
Sequencing experiment. fcDNA was subjected to methy-
lation enrichment without any additional fragmentation,
while DNA fully methylated in vitro with SSSI enzyme
(Millipore), which was used as a methylation positive
control, was fragmented using a Branson Digital Sonifier
Model 450 probe sonicator (Branson Ultrasonics Corpor-
ation, USA) to a size range of around 100–500 bases.
100 ng of the SSSI methylation positive control DNA was
processed in parallel with the fcDNA samples.
PCR DNA quantification
Quantitative PCR was carried out on a Corbett RotorGene
2000 machine (Sydney, Australia) in a 20 μL reaction
volume containing 0.6 U Taq Polymerase (Roche), 1X
PCR reaction buffer (Roche), 0.2 mM dNTP (Roche),
0.4 μM of each primer, 3% DMSO, and SYBR green I
(Invitrogen) at a final dilution of 1/25000. Following initial
denaturation for 8 minutes at 95°C, the PCR cycles were
as follows: 10 sec at 95°C, annealing for 45 sec at 60°C, ex-
tension for 30 sec at 72°C, with a data acquisition step at
the end of the extension. Primers targeting the promoter
region of the SFN1 gene (F – GCCAAGAGCAGGAGAG
ACAC; R – TTGGCCTTCTGGATCAGACT) or the
SFTA3 gene (F –AGCCTCTTTCTTGCCATCAA; R –
ACGCTTCAGATTGCGTTCTA) were used for data in
the main figures. These genes were selected as we have
found these reactions to be particularly robust and sen-
sitive. In addition, the SFTA3 promoter is found to be
unmethylated in PBMCs (data not shown), hence this
assay is suitable for comparing yields of unmethylated
(PBMC) and in vitro methylated (SSSI treated) DNA.
For the DNA quantitation shown in Additional file 1:
Figure S1, TaqMan RNAse P primers (Invitrogen) were
used following manufacturer’s instructions. For all PCR
quantitation assays, DNA concentration was determined
by comparison against a standard curve of genomic DNA.
Next-Generation Sequencing and analysis
Next-Generation Sequencing to generate 50-base, single-
end reads was carried out on the Illumina HiSeq2000 plat-
form (The Ramaciotti Centre for Gene Analysis, UNSW).
The sequencing library was prepared using the ChIP-Seq
DNA Sample Preparation Kit from Illumina, following the
manufacturer’s instructions from the “Preparing Samples
for ChIP Sequencing of DNA” booklet (2007). A modifica-
tion was introduced at the library size restriction step with
the use of the Pippin Prep (Sage Science) to collect a size
range corresponding to 180 ± 50 base DNA fragments in
order to be certain of capturing the 180 base fcDNA band,
taking into account the additional length of the adapters
and primers which added 92 bases to the fragments.
Successful library purification was verified by running
the DNA on an Agilent 2100 Bioanalyzer High Sensitivity
Chip in combination with fluorescence measurements by
the QuBit fluorometer (Invitrogen) to check for recovery.
Basic quality control checks and % GC content cal-
culations were carried out using FastQC (http://www.
bioinformatics.bbsrc.ac.uk/projects/fastqc) and sequences
were mapped to the Hg19 version of the human genome
using Bowtie [19], allowing for up to 3 mismatches.
Uniquely aligned reads were used in subsequent ana-
lyses. Visualization and analysis were carried out in
IGV [20] and Galaxy (https://usegalaxy.org/). Peaks of
methylated regions were called via the MACS algorithm
[21] and library fragment size was estimated using
Homer DNA analysis software [22].
Clonal bisulphite sequencing
Primers (Additional file 1: Table S1) were designed to
amplify both methylated and unmethylated bisulphite
converted DNA. PCR conditions for unbiased and specific
amplification were determined using different MgCl2 gra-
dient and PCR annealing temperatures on DNA from the
double knock-out cell line HCT116 (unmethylated con-
trol) and the same cell line DNA enzymatically methylated
in vitro (fully methylated control) (Zymo). Bisulphite con-
version was carried out on fcDNA donor sample 5 using
the Epitect kit (Qiagen). Having identified the appropriate
PCR conditions, 150 ng total fcDNA was bisulphite con-
verted using the “Small Amounts of Fragmented DNA”
protocol from the Epitect Kit, PCR amplified, and cloned
into the pCR2.1 vector using the TA Cloning Kit (Invitro-
gen) following manufacturer’s instructions. Bacterial col-
onies with positive clones were chosen using blue-white
selection on IPTG/X-gal plates. Sanger sequencing was
carried on 12–13 clones for each amplicon (Additional
file 1: Table S1), using standard protocols.
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Results and discussion
fcDNA holds great promise as a non-invasive source for
real-time disease markers, and thus has multiple useful
clinical applications. Because it is typically found at very
low concentrations in plasma, successful downstream ana-
lysis requires prompt sample processing and standardized
protocols that can accommodate very small amounts of
input material. However, there are currently no definitive
standards for blood collection and processing, and fcDNA
extraction. We sought to standardize methodology for
sample storage, processing and scaling, to recover optimal
fcDNA quantities and quality for downstream whole-
genome analysis.
Comparison of plasma and serum
To date, most publications describing fcDNA studies
have utilized either serum or plasma as their DNA
source, with higher yields of fcDNA being reported from
serum than from plasma [3,4,23-25]. However, it is cur-
rently unclear whether the quality of fcDNA extracted
from serum versus plasma is comparable. To address
this, we compared yields and visualization of fcDNA ex-
tracted from equivalent volumes (4 mL) of serum or
plasma from the same donors. A higher yield of DNA
was observed from serum (32.7 ± 19.9 ng/mL) than from
plasma (3.6 ± 0.5 ng/mL) (Figure 1A). The increased
yield from serum has been postulated to be due to con-
tamination with genomic DNA released from leukocytes
which lyse during the clotting and centrifugation pro-
cedures undertaken in serum collection [25]. In order
to determine whether high molecular weight genomic
DNA was present in our samples, we visualized the
plasma- and serum-derived fcDNA on an agarose gel.
The fcDNA appeared as a band at ~180 base pairs, and
a minor band between 300–400 base pairs (Figure 1B,
Lanes 1 and 2), reflecting the fcDNA fragments, similar
to previous reports [1,2]. We did not detect a band
corresponding to genomic DNA in either sample type.
To eliminate the possibility that high molecular weight
DNA released during blood processing was not detect-
able on a gel because it was degraded by active nucle-
ases, serum and plasma blood collection tubes were
pre-loaded with purified leukocyte genomic DNA prior
to sample collection. Blood was then collected into the
pre-loaded tubes, and plasma or serum was separated.
The fcDNA was then extracted and visualized on an
agarose gel (Figure 1B, Lanes 3 and 4). The genomic
DNA that we had pre-loaded in the plasma tube was re-
covered and visible as a high-molecular weight band
co-migrating with purified genomic DNA (Figure 1B,
Lane 5), while no corresponding band was visible in the
serum isolated from the pre-loaded tube.
This finding that we were unable to recover spiked
genomic DNA from serum suggests that DNA released
from leukocytes during clot formation and centrifuga-
tion could be degraded by the DNAses that are active in
Figure 1 Comparison of fcDNA isolation from plasma and serum. (A) PCR quantitation of fcDNA obtained from 200 μL plasma and serum
samples. Bars represent the average concentration fold change in matched serum and plasma samples obtained from 3 separate donors ± SD.
(B) Lane 1: fcDNA isolated from 4 mL serum; Lane 2: fcDNA isolated from 4 mL plasma; Lane 3: genomic DNA spiked into serum sample prior to
fcDNA processing; Lane 4: genomic DNA spiked into plasma sample prior to fcDNA processing; Lane 5: genomic DNA. Arrow: high molecular
weight genomic DNA; MWM: molecular weight marker.
Warton et al. BMC Genomics 2014, 15:476 Page 5 of 13
http://www.biomedcentral.com/1471-2164/15/476
serum, such as DNAse1 and DNAse1l3 [26]. As genomic
DNA spiked into plasma tubes is not degraded, the re-
sponsible DNAse is likely inhibited by the EDTA present
in the plasma tube to prevent blood clotting. We also
note that there is an apparent increase in the 180 bp
band in the serum sample spiked with genomic DNA
(Figure 1B, Lane 3). This increase was consistently ob-
served across repeat experiments using blood samples
from different donors (data not shown). As it is unlikely
that the spiked nucleosome-free genomic DNA would
be degraded to regular sized fragments, this increase
may represent additional leukocyte lysis stimulated by
the presence of naked DNA in the sample; however a
more detailed investigation of this point is beyond the
scope of this study.
Effect of blood storage times on plasma and serum DNA
concentration
As research laboratories are frequently at some distance
from the clinical facilities where biospecimens are col-
lected from patients, leading to delays between sample
collection and processing, we sought to determine an ac-
ceptable time interval between blood collection and
plasma or serum separation prior to fcDNA extraction.
To examine the effects of blood storage times on the cell
free DNA content, we collected blood from healthy vol-
unteers and either processed it immediately, or stored it
at 4°C for 4 hrs, 8 hrs, 24 hrs or 48 hrs prior to plasma
or serum separation. fcDNA was then extracted from
4 mL plasma or 3 mL of serum, quantitated by qPCR
and examined on a gel to determine its stability over
time (Figure 2). We observed no change in DNA content
in plasma up to 8 hrs (range 4.4-4.9 ± 1.3 ng/mL); however
DNA concentrations in the plasma increased steadily at
24 (6.5 ± 2.2 ng/mL) and 48 hrs (10.8 ± 4.5 ng/mL) after
storage (Figure 2A). In contrast, serum DNA concentra-
tion was increased by 4 hours, and continued to increase
as the blood was stored over time (Figure 2C). In order
to examine the fcDNA and determine what may be
contributing to the increased concentrations during
storage, the samples were visualized on an agarose gel
(Figure 2B and D). At each time point examined, the
plasma samples contained a strong band at ~180 bp, and
a minor band between 300 bp and 400 bp (Figure 2B,
Lanes 1–4), representing the fcDNA fragments, while
the 24 hr and 48 hr time points also contained a high
molecular weight DNA band, which appeared in parallel
to the increase in DNA concentration shown in Figure 2A.
As this high molecular weight band co-migrates with
purified genomic DNA (Figure 2B, Lane 5), it most
likely represents DNA released from leukocytes which
lysed during blood storage. The gel of DNA extracted
from the serum samples also shows a clear increase in
the DNA with increasing blood storage times, but no
high molecular weight band is apparent; rather, there is
an increase in laddered DNA (Figure 2D, Lanes 1–5).
This suggests that during blood clotting and storage,
leukocytes either undergo apopotosis, producing the
characteristic DNA cleavage pattern, or that serum active
nucleases cleave DNA released from lysed leukocytes
inter-nucleasomally.
Although storage of blood prior to plasma and serum
separation introduces DNA into the sample which differs
in size depending on the sample type, the most likely
source of this DNA in either case is lysis of leukocytes
during storage and release of their DNA into the blood,
thereby contaminating any fcDNA present in the sample.
Therefore, if fcDNA studies intend to investigate shed
cell-free DNA found in the circulation, we recommend
that the maximum time that blood samples should be
stored prior to plasma separation is 8 hrs, whereas serum
samples should be processed immediately to prevent con-
tamination with genomic DNA. This is in agreement with
previous reports of artifacts introduced through storage of
blood samples prior to processing [23]. Furthermore, we
note that lack of a high molecular weight band in serum is
not indicative of absence of genomic DNA contamination,
and previous work using male white blood cells spiked
into female derived blood samples has determined that
leukocytes lyse during the process of clotting [25]. There-
fore, in order to avoid potential genomic DNA contamin-
ation in fcDNA studies, plasma should be the preferred
source for fcDNA extraction.
fcDNA purification from large plasma volumes
Once we developed optimized protocols for blood collec-
tion and fcDNA processing, we undertook a study to cap-
ture and sequence methylated fcDNA from 5 volunteer
blood donors. In order to isolate sufficient fcDNA from
blood for methylation enrichment and Next-Generation
Sequencing, fcDNA must be extracted from large volumes
of plasma, indicating a need to scale up standard DNA
isolation protocols while avoiding excessive dilution. The
QIAamp Circulating Nucleic Acids kit (Qiagen) specifies
plasma volumes of up to 5 mL; however, for whole-
genome analysis of methylated fcDNA, which represents a
small fraction of total fcDNA, an input volume of at least
35 mL is necessary. For our studies, we modified the
standard Qiagen protocol for increased plasma volumes,
including proportional scaling up of the proteinase K and
ACL buffer. At the column binding step this volume was
split across two columns (17.5 mL each), and the eluted
DNA for each sample was pooled. While the time for
sample processing was increased, we did not encounter
any issues with column blockage at these larger volumes.
A pilot experiment was carried out to show that propor-
tional yield did not decrease with scaling up to a volume
of 17.5 mL (Additional file 1: Figure S1).
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DNA isolation and methylation enrichment from modified
MethylMiner protocol
The plasma concentration of fcDNA isolated from
35 mL of plasma in 5 control subjects ranged from 6.9 –
10.7 ng/ml plasma (Table 1), comparable with concen-
trations previously reported for healthy individuals [8].
The size distribution of the fcDNA was visualized on an
Agilent Bioanalyzer chip. As expected, we observed a
very strong band at 180 base pairs, with fainter, more
diffuse bands at 300–400 base pairs (Figure 3A). The
next step involved application of a methyl-binding
protein capture protocol (MBD-cap) to capture methyl-
ated fragments from total fcDNA isolated from plasma.
Because our starting fcDNA concentrations were low
(Table 1), we investigated the efficiency of MBD-capture
to ensure specific enrichment of methylated fragments.
Using peripheral blood mononuclear cell (PBMC) DNA
and methylation-positive SSSI DNA, we quantitated DNA
recovery by qPCR of the SFTA3 promoter region follow-
ing MBD-capture of low (100 ng) and standard (400 ng)
DNA inputs (Figure 3C), using both the standard cap-
ture protocol and our modified protocol. As SFTA3 is
Figure 2 Contamination of fcDNA with genomic DNA during blood storage. Concentration change of DNA extracted from plasma (A) or
serum (C) measured by PCR at 0 hr, 4 hr, 8 hr, 24 hr and 48 hr following blood collection. Each bar represents the average concentration fold
change of triplicate (A) or duplicate (C) experiments ± SD. (B) fcDNA isolated from 4 mL plasma immediately (Lane 1), 8 hrs (Lane 2), 24 hrs
(Lane 3) and 48 hrs (Lane 4) following blood collection. Lane 5: genomic DNA. (D) fcDNA isolated from 3 mL serum immediately (Lane 1), 4 hrs
(Lane 2), 8 hrs (Lane 3), 24 hrs (Lane 4) and 48 hrs (Lane 5) following blood collection. Lane 6: genomic DNA. Arrow: High molecular weight
genomic DNA; MWM: molecular weight marker.
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unmethylated in PBMC and methylated in SSSI DNA,
we expect low recovery of SFTA3 from PBMC DNA and
high recovery from SSSI DNA. Our studies determined
that with low DNA input, the standard MBD-cap protocol
results in high levels of background binding of DNA to
the MBD-linked beads, and thus only minor enrichment
of methylated sequences (Figure 3C, 100 ng, grey bars),
whereas with standard DNA inputs, background binding
is proportionately significantly decreased and methylation
enrichment reaches at least 7-fold (Figure 3C, 400 ng, grey
bars). Because our total fcDNA input was ~50 ng (Table 1),
we modified the standard protocol to minimize the non-
specific DNA binding at low inputs. Specifically, we de-
creased the volume of beads used from 10 μL to 1 μL,
Table 1 Concentration of fcDNA in 5 control subjects and DNA quantitation at consecutive stages of sample processing
Sample Plasma fcDNA
concentration (ng/mL)
MethylMiner
input (ng)
MethylMiner
recovery (ng) (%)
Illumina NGS* input for
library generation (ng)
Amount of library
generated (ng)
1 6.9 48.7 5.04 (10.4) 4 464
2 7.3 49.6 5.04 (10.2) 4 245
3 7.8 49.5 5.73 (11.6) 4 314
4 9.9 42.2 6.28 (14.9) 4 39
5 10.7 43.2 5.32 (12.3) 4 222
*NGS = Next-Generation Sequencing.
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Figure 3 Size distribution of fcDNA in 5 control samples and following fcDNA library construction (A and B) and DNA recovery
following MBD-capture (C). Agilent Bioanalyzer chip with fcDNA isolated from 5 control subjects prior to (A) and following (B) methylation
enrichment and library preparation. Increase in molecular weight reflects successful adapter ligation. MWM: molecular weight marker. DNA
recovery following MBD-capture (C). Recovery of DNA (based on % of input DNA) as quantitated by qPCR following the standard (grey bars) or
our modified (white bars) MBD-capture protocol. SFTA3 promoter is unmethylated in PBMC DNA and methylated in the methylation positive
control SSSI. At low DNA inputs (100 ng), SFTA3 is recovered from both PBMC and SSSI DNA, suggesting high background MBD binding and low
methylation enrichment. With our modified protocol, SFTA3 is minimally recovered from PBMC DNA (unmethylated) but is recovered from SSSI
DNA (methylated), even at low DNA inputs. Data is presented as % DNA recovery ± range.
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and increased the stringency of the Bind/Wash buffer
to 300 mM NaCl. Using this modified MBD-cap proto-
col, background binding of DNA to the MBD-linked
beads was minimal even at low DNA inputs, with
methylation enrichment reaching 30-fold (Figure 3C,
white bars). Thus, our modified MBD-cap protocol allows
for low background binding and specific enrichment of
methylated fragments from low DNA inputs. This modi-
fied protocol was then applied to our fcDNA samples, and
the percent recovery of methylated DNA following our
modified MBD-capture protocol ranged from 10.2-14.9%
(Table 1), comparing well with the approximately 7% re-
covery previously described in the literature [17]. There
are currently a number of methylation-capture kits avail-
able (recently evaluated for performance in [27]), which
may perform at various levels based on the biological
sample input.
Library preparation
The methylation-enriched fcDNA samples were then
prepared for Illumina Next-Generation Sequencing. MBD-
capture followed by sequencing is conceptually similar
to ChIP-Seq where fragments of DNA are captured by
specific binding to an antibody directed against a tran-
scription factor; however in place of the antibody a do-
main of the methyl binding protein MBD2 is used.
Thus, we applied a modified version of the Illumina
protocol “Preparing Samples for ChIP Sequencing of
DNA” to generate the sequencing library. Because our
fcDNA input was less than half of the minimum DNA
input required by Illumina, we took advantage of the
discrete size of fcDNA to minimize sample loss during
library preparation. In the ChIP-Seq protocol, DNA is
fragmented by sonication, producing fragments with a
range of sizes that run as a broad band/smear on an
agarose gel. During library preparation, fragments are
then size-restricted by excising a gel slice within the de-
sired size range and re-purifying the DNA from this
slice. We reasoned that a significant loss of input DNA
occurs at the size restriction step, as most of the DNA is
left behind in the agarose gel since it falls outside the
appropriate size range. fcDNA samples would not be
subjected to this loss, since the DNA is of a uniform
size, and runs predominantly as a single band which
could be recovered in its entirety from within the gel
slice. Because of this advantage, we postulated that li-
braries of good complexity could still be generated from
fcDNA inputs considerably less than 10 ng minimum
specified by the Illumina protocol. This approach restricts
the DNA captured to the lowest molecular weight band,
and excludes high molecular weight DNA; however,
previously reported whole genome sequencing of the
low molecular weight fraction of fcDNA was able to
clearly distinguish between control and cancer samples,
indicating that this fraction contains sufficient DNA to
be detectable by NGS [14].
We used an input amount of 4 ng fcDNA for the proto-
col, and recovered 39–464 ng following library prepar-
ation (Table 1). The prepared libraries were visualized on
a Bioanalyzer Chip (Figure 3B). The size of the libraries
ranged from 266 bases to 269 bases, which is in good
agreement with the expected size of 272 bases (180 base
DNA fragments plus 92 base adapters), indicating that we
were able to obtain good quality and complete libraries
with less than half of the required amounts of DNA. The
length of the sequenced fragments, excluding adapters,
was further validated using the Homer tag autocorrelation
function [22], in which the position of each read is cal-
culated relative to every other read on the same chromo-
some. This analysis revealed an average sequence fragment
length estimate of 170 bases, ranging between 165 and
173 bases across the 5 sequenced samples (data not
shown), consistent with the size of the fcDNA observed
on the Bioanalyzer chip.
Next-Generation Sequencing results and quality control
Our 5 fcDNA samples were then submitted for 50-base,
single-end Next-Generation Sequencing. Read numbers
are presented in Table 2. We obtained 37×106 to 86×106
unique mappable reads per sample, which is well above
Table 2 Descriptions of Next-Generation Sequencing read numbers
Sample Total reads1 Unaligned2 Multiple site aligned3 Single site aligned4 Unique5 % Unique
1 197,921,529 16,066,294 44,319,996 137,535,239 76,590,535 55.7
2 199,302,552 15,885,135 43,676,951 139,740,466 77,836,232 55.7
3 108,955,707 8,729,606 26,671,313 73,554,788 43,869,724 59.6
4 109,132,802 11,042,561 24,138,010 73,952,231 37,270,330 50.4
5 200,639,214 15,558,416 44,708,970 140,371,828 85,538,368 60.9
1Total reads obtained.
2Reads which could not be aligned to a site within the human genome.
3Reads which could not be accurately mapped since they aligned to multiple sites within the human genome.
4Reads which aligned to a single site within the human genome.
5Unique reads which aligned to a single site within the human genome.
6Unique reads as a percentage of the reads which could be aligned at a single site within the genome.
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the 10x106 unique mappable reads per biological repli-
cate suggested as a minimum for ChIP-seq experiments
in mammalian cells by the ENCODE consortium [28].
For all samples, unique mappable reads represented more
than 50% of the total mappable reads, indicating that
despite the relatively low DNA input amounts, a good
level of library complexity was achieved [29].
Quality control checks were carried out on obtained
reads using FastQC, and showed that base quality scores
were consistently high (>28) for all samples (Additional
file 1: Figure S2). The quality control analysis also re-
vealed that we did not observe the expected normal dis-
tribution of % GC content across 50-base sequencing
reads (Figure 4A, blue line, centered at 59%). Instead we
Figure 4 % GC distribution of sequenced reads. (A) Expected (blue line) and actual (red line) % GC content present in total sequenced reads.
Representative reads from a single sample are shown. (B) Elucidation of source of high and low % GC peaks in the sequencing reads. Model
depicts captured fcDNA fragments (blue lines with sequenced 50 base reads shown on ends) containing methylated CpG sites which allow for
capture (red circles). Arrows indicate the contribution of each read to the low % GC peak (methylated CpG sites are located in the middle of the
fragment and thus fall outside 50 base read) and the high % GC peak (methylated CpG sites are located near the edge of the fragment and thus
contained within 50 base read). (C) Expected (blue line) and actual (red line) % GC content present in non-overlapping sequenced reads.
Representative reads from a single sample are shown.
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observed a bimodal distribution of % GC content, with
one (high) peak centered on 59% GC, and the other
(low) peak centered on 39% GC (Figure 4A, red line).
We postulated that this bimodal distribution reflects se-
quenced reads that either overlap with the CpG sites
that allowed MBD capture in each fragment (corre-
sponding to high % GC reads), or that fall outside the
CpG sites that led to the capture of the DNA fragment
(corresponding to low % GC reads). Because the sequen-
cing process starts at one end of the fcDNA fragment
and reads the 50 bases adjacent to that end, sequence
reads will either overlap with methylated CpG sites if
they are located near the end of fcDNA fragments, thus
displaying a high % GC peak, or they will sequence out-
side methylated CpG sites if they are located in the mid-
dle of fcDNA fragments, thus displaying a low % GC
peak (Figure 4B). To test this model, we used FastQC to
calculate the expected and actual % GC content of se-
quenced reads positioned at the outer edge of called
peaks of methylated regions, which would not overlap
with the methylated CpG sites allowing for capture of
the fcDNA fragment. The GC plots generated from
these reads correspond to the low GC content peak
(39%) of the bimodal distribution, whereas the high GC
content peak (59%) is no longer present (Figure 4C).
These results support the notion that the bimodal % GC
distribution seen across all 50-base sequencing reads is
driven by the position of methylated CpG sites of each
captured DNA fragment either overlapping the sequenced
end or falling outside of it.
Sequencing validation
In order to validate our sequencing results, and verify
that our sequenced fragments specifically represented
methylated fcDNA regions captured by binding to the
MBD2 protein rather than DNA which had non-
specifically bound to the bead matrix or the plastic-
ware, we carried out bisulphite conversion and clonal
Figure 5 Clonal bisulphite sequencing of fcDNA from sample 5. (A) Validation of 3 promoter regions found to be methylated in SSSI positive
control (green) and in fcDNA (blue). (B) Validation of 3 promoter regions found to be methylated SSSI positive control (green) but not in fcDNA
(blue). (C) Validation of 3 loci found to be unmethylated in SSSI positive control (green) but methylated in fcDNA (blue). Closed circles indicate
methylated CpGs as determined by clonal bisulphite sequencing; open circles indicate unmethylated CpGs as determined by clonal bisulphite
sequencing; grey arrows indicate transcriptional start sites; red rectangles indicate the regions sequenced for validation.
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sequencing on selected regions in pre-methylation-
enriched fcDNA from sample 5. We selected 3 regions
that appeared methylated in the fcDNA and in the
methylation positive control sample (FTMT, C1orf177
and KCNE4 promoter regions) (Figure 5A), 3 regions that
appeared unmethylated in the fcDNA and methylated in
the positive control sample (C10orf114, GAPDH and
GSTP1 promoter regions) (Figure 5B), and 3 regions that
appeared methylated in the fcDNA despite no signal being
observed in the methylation positive control (BCL2 and
SATB2 gene body regions) (Figure 5C). DNA was bisul-
phite converted, PCR-amplified, cloned, and 12–13 clones
were sequenced for each region. In all 9 examined gen-
omic regions, the clonal bisulphite sequencing results
were concordant with the methylation results from the
MBD-capture and Next-Generation Sequencing. We pos-
tulate that the lack of signal in the methylation positive
control shown in Figure 5C is due to either incomplete
in vitro enzymatic methylation, or to regions with sparse
CpGs being out-competed from the MBD-binding sites by
the abundant dense methylation in the remainder of the
positive control DNA. In either case, the clonal bisulphite
sequencing results demonstrate that the sequencing reads
obtained for these genomic regions in the fcDNA samples
do not represent false positives. These results provide fur-
ther support that whole-genome analysis of even small
amounts of fcDNA can provide high-quality, validated
genomic data that strengthen the potential of fcDNA util-
ity in clinical applications.
Conclusions
While tissues and cell lines are readily amenable to meth-
ylated DNA capture and sequencing due to the relatively
large amounts of starting material typically available, se-
quencing of the methylated fraction of fcDNA has not
previously been reported, most likely due to the technical
challenges presented by working with very small amounts
of input DNA. We developed and applied modified pro-
tocols for plasma DNA extraction, methylated sequence
enrichment and sequencing library construction, allowing
us to obtain high numbers of good quality unique reads
from methylated fcDNA samples. This approach allows
in-depth genomic characterization made possible by Next-
Generation Sequencing to be applied to tiny amounts of
methylated fcDNA, for investigating biological mecha-
nisms and developing diagnostic applications.
Additional file
Additional file 1: Table S1. Primer sequences and conditions used for
unbiased amplification of methyated and unmethylated
bisulphite-converted DNA. Figure S1. fcDNA quantitation by PCR. fcDNA
concentration (ng) in 250 μl eluent from 5, 10 and 17.5 ml plasma
samples. Each bar represents the average of duplicate experiments ±
range. Figure S2. Sequence read quality for 5 fcDNA samples. Illumina
sequence read quality in 5 fcDNA samples for each base pair (bp)
position across the 50-bp reads. Q scores >28 (green section) are
considered high-quality.
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